Graft-versus-host disease and immunologic rejection: implications for diagnosis and treatments of pregnancy complications

References

• Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricodi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet339, 1579–1582 (1992).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Lakkis FG. The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology43(2 Suppl. 1), S151–S163 (2006).
   Google Scholar
• Bettens F, Tiercy JM, Campanile N et al. Microchimerism after liver transplantation: absence of rejection without abrogation of antidonor-cytotoxic T-lymphocyte mediated alloreactivity. Liver Transpl.11, 290–297 (2005).
   PubMed Web of Science ®Google Scholar
• Olszewski WL, Iterewicz B, Maksymovicz M, Stanislawska J. Transplantation of organs is transplantation of donor DNA: fate of DNA disseminated in recipient. Transpl. Int.18, 412–418 (2005).
   PubMed Web of Science ®Google Scholar
• Crispim JC, Wastowski IJ, Faggioni LP, Costa R, Saber L, Donadi EA. Microchimerism evaluation in recipients of living-related or unrelated deceased allograft renal transplants. Transplant. Proc.38, 2828–2830 (2006).
   PubMed Web of Science ®Google Scholar
• Gaia S, Cappia S, Smedile A et al. Epithelial microchimerism: consistent finding in human liver transplants. J. Gastroenterol. Hepatol.21, 1801–1806 (2006).
   PubMed Web of Science ®Google Scholar
• Pollack MS, Speeg KV, Callander NS et al. Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum. Immunol.66, 28–31 (2005).
   PubMed Web of Science ®Google Scholar
• Araujo MB, Leonardi LS, Boin IF et al. Molecular mechanisms associated with donor-specific microchimerims in peripheral blood of Brazilian patients after liver transplantation. Transplant. Proc.38, 1411–1417 (2006).
   PubMed Web of Science ®Google Scholar
• Weinstein A, Dexter D, KuKuruga DL, Philosophe B, Hess J, Klassen D. Acute graft-versus host disease in pancreas transplantation: a comparison of two case presentations and a review of the literature. Transplantation,82, 127–131 (2006).
   PubMed Web of Science ®Google Scholar
• Smith DM, Agura ED, Ausloos K, Ring WS, Domiati-Saad R, Klintmalm GB. Graft-vs-host disease as a complication of lung transplantation. J. Heart Lung Transplant.25, 1175–1177 (2006).
   PubMed Web of Science ®Google Scholar
• Rowe V, Banovic T, Mac Donald KP et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood108, 2485–2492 (2006).
   PubMed Web of Science ®Google Scholar
• Koopmans M, Kremer-Hovinga IC, Baelde HJ et al. Chimerism in kidneys, livers and hearts of normal women: implications for transplantation studies. Am. J. Transplant.5, 1495–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Davies CJ. Why is the fetal allograft not rejected? J. Anim. Sci.85(13 Suppl.), E32–E35 (2006).
   Google Scholar
• Mosebach M, Pakner A, Jakubiczka S, Wieacker P, Heim MU. Dispermic chimerism identified during blood group determination and HLA typing. Transfusion46, 1978–1981 (2006).
   PubMed Web of Science ®Google Scholar
• Williams CA, Wallace MR, Drury KC et al. Blood lymphocyte chimerism associated with IVF and monochorionic dizygous twinning: case report. Hum. Reprod.19, 2816–2821 (2004).
   PubMed Web of Science ®Google Scholar
• Drexler C, Wagner T. Blood group chimerism. Curr. Opin. Hematol.13, 484–489 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson KL, Bianchi DW. Fetal cells in maternal tissue following pregnancy: what are the consequences? Hum. Reprod. Update10, 497–502 (2004).
   PubMed Web of Science ®Google Scholar
• Khosrotehrani K, Bianchi DW. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J. Cell Sci.118, 1559–1563 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson JL. Microchimerism in human health and disease. Autoimmunity36, 5–9 (2006).
   Google Scholar
• Lo YMD, Lau TK, Chan LYS, Leung TN, Chang AMZ. Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin. Chem.46, 1301–1309 (2000).
   PubMed Web of Science ®Google Scholar
• Kolialexi A, Tsangaris GT, Antsklis A, Mavroua A. Rapid clearance of fetal cells from materntal circulation after delivery. Ann. NY Acad. Sci.1022, 113–118 (2004).
   PubMed Web of Science ®Google Scholar
• Ariga H, Ohto H, Busch MP et al. Kinetics of fetal cellular and cell-free DNA in maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion41, 1524–1530 (2001).
   PubMed Web of Science ®Google Scholar
• Artlett CM, Cox LA, Ramos RC et al. Increased microchimerism CD4+ T lymphocytes in peripheral blood from women with systemic sclerosis. Clin. Immunol.103, 303–308 (2002).
   PubMed Web of Science ®Google Scholar
• Lambert NC, Lo YM, Erickson TD et al. Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. Blood100, 2845–2851 (2002).
   PubMed Web of Science ®Google Scholar
• Ando T, Davies TF. Self-recognition and the role of fetal microchimerism. Best Pract. Res. Clin. Endocrinol. Metab.18, 197–211 (2004).
   PubMed Web of Science ®Google Scholar
• Gleicher N, Barad D. Gender as risk factor for autoimmune diseases. J. Autoimmun.28, 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Lambert NC, Erickson TD, Yan Z et al. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. Arthritis Rheum.50, 906–914 (2004).
   PubMed Web of Science ®Google Scholar
• Khosrotehrani K, Mery L, Aractingi S, Bianchi DW, Johnson KL. Absence of fetal cell microchimerism in cutaneous lesions of lupus erythematosus. Ann. Rheum. Dis.64, 159–160 (2005).
   PubMedGoogle Scholar
• Weger W, Bauer M, Odell E et al. Role of microchimerism in the pathogenesis of oral lichen planus. Exp. Dermatol.15, 125–129 (2006).
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type-1 – a meta analysis of 15 prospective cohort studies. N. Engl. J. Med.340, 977–987 (1999).
   PubMed Web of Science ®Google Scholar
• Harrison KL, Baker JW. Fetal-maternal macrotransfusion – a study of 400 postpartum women. Aust. NZ J. Obstet. Gynaecol.18, 176–178 (1978).
   PubMed Web of Science ®Google Scholar
• Gleicher N. Pregnancy-related cell traffic, microchimerism and autoimmunity: the possibility of reducing autoimmune disease prevalence. Expert Rev. Obstet. Gynecol.2, 341–345 (2007).
   Google Scholar
• Bianchi DW, Williams JM, Sullivan LM, Hanson FW, Klinger KW, Shuber AP. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am. J. Hum. Genet.61, 822–829 (1997).
   PubMed Web of Science ®Google Scholar
• Wataganara T, LeShane ES, Farina A et al. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum. Genet.112, 204–208 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer M, Hutterer G, Eder M et al. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. Prenat. Diagn.26, 831–836 (2006).
   PubMed Web of Science ®Google Scholar
• Bianchi DW, Farina A, Weber W et al. Significant fetal-maternal hemorrhage after termination of pregnancy: implications for development of fetal cell microchimerism. Am. J. Obstet. Gynecol.184, 703–706 (2001).
   PubMed Web of Science ®Google Scholar
• Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW. The influence of fetal loss on the presence of fetal cell microchimerism: a systemic review. Arthritis Rheum.48, 3237–3241 (2003).
   PubMed Web of Science ®Google Scholar
• Holzgreve W, Ghezzi F, di Naro E, Ganshirt D, Maymon E, Hahn S. Disturbed feto–maternal cell traffic in preeclampsia. Obstet. Gynecol.91, 669–672 (1998).
   PubMed Web of Science ®Google Scholar
• Lo YMD, Leung TN, Tein MSC et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsisa. Clin. Chem.45, 184–188 (1999).
   PubMed Web of Science ®Google Scholar
• Hahn S, Holzgreve W. Fetal cells and cell-free fetal DNA in maternal blood: new insights into pre-eclampsia. Hum. Reprod. Update8, 501–508 (2002).
   PubMed Web of Science ®Google Scholar
• Gleicher N. Why much of the pathophysiology of preeclampsia/eclampsia has to be ‘autoimmune’ in nature. Am. J. Obstet. Gynecol.196(1), 5.e1–5.e7 (2007).
   PubMed Web of Science ®Google Scholar
• David M, Smidt J, Chen FC, Stein U, Dudenhausen JW. Risk factors for fetal-to-maternal transfusion in Rh D-negative women – results of a prospective study of 842 pregnant women. J. Perinat. Med.32, 254–257 (2004).
   PubMed Web of Science ®Google Scholar
• Gleicher N, Pratt D, Dudkiewicz A. What do we really know about autoantibody abnormalities and reproductive failure: a critical review. Autoimmunity16, 115–140 (1993).
   PubMed Web of Science ®Google Scholar
• Bianchi DW, Romero R. Biological implications of bi-directional fetomaternal cell traffic: a summary of a national Institute of Child Health and Human Development-sponsored conference. J. Matern. Fetal. Neonatal. Med.14, 123–129 (2003).
   PubMedGoogle Scholar
• Norwitz ER. Defective implantation and placentation: laying the blueprint for pregnancy complications. Reprod. Biomed. Online13, 591–599 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA, Maternal–fetal disparity in HLA class II alloantigens and pregnancy-induced amelioration of rheumatoid arthritis. N. Engl. J. Med.329, 466–471(1993).
   PubMed Web of Science ®Google Scholar
• Farley DM, Grainger DA, Tjaden BL, Frazier LM, Maki JR. Use of gestational carrier for a patient with recurrent adverse pregnancy: outcomes from early onset severe preeclampsia. Fertil. Steril.87, 189 (2007).
   PubMedGoogle Scholar
• Nelson JL, Furst DE, Maloney S et al. Microchimerism and HLA-compatible relatiosnships of pregnancy in scleroderma. Lancet351, 559–562 (1998).
   PubMed Web of Science ®Google Scholar
• Lambert NC, Evans PC, Hashizumi TL et al. Cutting edge: perisisten fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J. Immunol.164, 5545–5548 (2000).
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Roberts IA, Kumar S, Bennet PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver and bone marrow. Blood98, 2396–2402 (2001).
   PubMed Web of Science ®Google Scholar
• O’Donoghue K, Chan J, de La Fuente J et al. Microchimerism in female bone marrow and bone decades after mesenchymal stem-cell trafficking in pregnancy. Lancet364, 179–182 (2004).
   PubMed Web of Science ®Google Scholar
• Donckier V, Troisi R, Toungouz M et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl. Immunol.13, 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Donckier V, Troisi R, Le Moine A et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl.12, 1523–1528 (2006).
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet363, 1439–1441 (2004).
   PubMed Web of Science ®Google Scholar
• Ringden O, Uzunel R, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation27, 1390–1397 (2006).
   Google Scholar
• Iwaki Y, Cecka JM, Terasaki PI. The transfusion effect. Clin. Transpl.283–292 (1988).
   PubMedGoogle Scholar
• Siemionow M, Agaoglu G. Role of blood transfusion in transplantation: a review. J. Reconstr. Microsurg.21, 555–563 (2005).
   PubMed Web of Science ®Google Scholar
• Posthuma EF, Marijt EW, Barge RM et al. α-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remission and is associated with acceptable graft-versus-host disease. Biol. Blood Marrow Transplant.10, 204–212 (2004).
   PubMed Web of Science ®Google Scholar
• Feeney JG, Tovey LA, Scott JS. Influence of previous blood-transfusion on incidence of pre-eclampsia. Lancet1, 874–875 (1977).
   PubMed Web of Science ®Google Scholar
• Ober C, Karrison T, Odm RR et al. Mononuclear-cell immunization in prevention of recurrent miscarriages: a randomized trial. Lancet31, 365–369 (1999).
   Google Scholar
• Porter TF, Scott JR. Alloimmune causes of recurrent pregnancy loss. Semin. Reprod. Med.18, 393–400 (2000).
   PubMed Web of Science ®Google Scholar
• Cowchock FS, Smith JB, Davis S, Scher J, Batzer F, Corson S. Paternal mononuclear cell immunization therapy for repeated miscarriage: predictive variables for pregnancy success. Am. J. Reprod. Immunol.22, 12–17 (1990).
   PubMed Web of Science ®Google Scholar
• Carp HJ, Toder V, Mashiach S. Immunotherapy and habitual abortion. Am. J. Reprod. Immunol.28, 281–284 (1992).
   PubMed Web of Science ®Google Scholar
• Gatenby PA, Cameron K, Simens RJ et al. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial. Am. J. Reprod. Immunol.29, 88–94 (1993).
   PubMed Web of Science ®Google Scholar
• Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and meta analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am. J. Reprod. Immunol.32, 55–72 (1994). [Erratum: Am. J. Reprod. Immunol.32, 255 (1994)].
   PubMed Web of Science ®Google Scholar
• Daya S, Gunby J. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent spontaneous abortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am. J. Reprod. Immunol.32, 294–302 (1994).
   PubMed Web of Science ®Google Scholar
• Carp HJ, Toder V, Torchinsky A et al. Allogenic leukocyte immunization after five or more miscarriages. Recurrent Miscarriage Immunotherapy Trialists Group. Hum. Reprod.12, 250–255 (1997).
   PubMed Web of Science ®Google Scholar
• Steck T, Westphal E, Wurfel W. Maternal immunization by husband’s leukocytes for repeated fetal death associated with mild pre-eclampsia – case report with successful outcome. Arch. Gynecol. Obstet.252, 103–107 (1992).
   PubMed Web of Science ®Google Scholar
• Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res.12, 5615–5621 (2006).
   PubMed Web of Science ®Google Scholar
• Gleicher N, Beers P, Cohen CJ, Kerenyi TD, Gusberg SB. Leukocyte migration enhancement. III. Common denominators of pregnancy and malignancy. Am. J. Obstet. Gynecol.136, 5–10 (1980).
   PubMed Web of Science ®Google Scholar
• Gleicher N, Siegel I. Common denominators of pregnancy and malignancy. Prog. Clin. Biol. Res.70, 339–353 (1981).
   PubMedGoogle Scholar
• Shaaban AF, Kim HB, Gaur L, Liechty KW, Flake AW. Prenatal transplantation of cytokine-stimulated marrow improves early chimerism in resistant strain combination but results in poor long-term engraftment. Exp. Hematol.34, 1278–1287 (2006).
   PubMed Web of Science ®Google Scholar
• Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF. An epidemiologic study of contraception and preeclampsia. JAMA262, 3143–3417 (1989).
   PubMed Web of Science ®Google Scholar
• Einarsso JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am. J. Obstet. Gynecol.188, 1241–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Ness RB, Markovic N, Harger G, Day R. Barrier methods, length of preconception intercourse, and preeclampsia. Hypertens. Pregnancy23, 227–235 (2004).
   PubMed Web of Science ®Google Scholar
• Trupin LS, Simon LP, Eskenazi B. Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology7, 240–244 (1996).
   PubMed Web of Science ®Google Scholar
• Mahanty HD, Cherikh WS, Chang GJ, Baxter-Lowe LA, Roberts JP. Influence of pretransplant pregnancy on survival of renal allograft from living donors. Transplantation72, 228–232 (2001).
   PubMed Web of Science ®Google Scholar
• Loren AW, Bunin GR, Boudreau C et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.12, 758–769 (2006).
   PubMed Web of Science ®Google Scholar
• Flowers ME, Pepe MS, Longton G et al. Marrow transplantation for Fanconi anemia, with or without leukemic transformation: an update on the Seattle experience. Br. J. Haematol.74, 492–496 (1990).
   PubMed Web of Science ®Google Scholar
• Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. Am. J. Transplant.5, 2968–2973 (2005).
   PubMed Web of Science ®Google Scholar
• Van Besien K. Standardizing chronic graft-versus-host disease. Future Oncol.2, 459–462 (2006).
   PubMedGoogle Scholar
• Holinski S, Modersohn D, Proch C, Meyer R, Konertz W. Age-dependent chronic rejection after experimental heart transplantation. J. Heart Lung Transplant.25, 1099–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Melin-Aldana H, Thorman K, Duerst R, Kletzel M, Jacobsohn DA. Hepatic pattern of graft versus host disease in children. Pediatr. Blood Cancer49, 727–730 (2007).
   PubMed Web of Science ®Google Scholar
• Akpek G, Boitnott JK, Lee LA et al. Hepatitis variant of graft-versus-host disease after donor lymphocyte infusion. Blood100, 3903–3907 (2002).
   PubMed Web of Science ®Google Scholar
• Sohn SK, Kim DH, Baek JH et al. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant.37, 699–708 (2006).
   PubMed Web of Science ®Google Scholar
• Akpek G, Zahurak ML, Piantadosi S et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood97, 1219–1226 (2001). [Erratum, Blood99, 14 (2002)].
   PubMed Web of Science ®Google Scholar
• Akpek G, Lee SJ, Flowers ME et al. Performance of new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood102, 802–809 (2003).
   PubMed Web of Science ®Google Scholar
• Lee KH, Choi SJ, Lee JH et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica90, 939–948 (2005).
   PubMed Web of Science ®Google Scholar
• Denianke KS, Frieden IJ, Cowan MJ, Williams ML, Mccalmont TH. Cutaneous manifestations of maternal engraftment in patients with severe combined immunodeficiency: a clinopathologic study. Bone Marrow Transplant.28, 227–233 (2001).
   PubMed Web of Science ®Google Scholar
• Roger D, Vaillant L, Fignon A et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch. Dermatol.130, 734–739 (1994).
   PubMedGoogle Scholar
• Kroumpouzos G, Cohen LM. Pruritic folliculitis of pregnancy. J. Am. Acad. Dermatol.43, 132–134 (2000).
   PubMed Web of Science ®Google Scholar
• Kroumpouzos G, Cohen LM. Dermatoses of pregnancy. J. Am. Acad. Dermatol.45, 1–19 (2001).
   PubMed Web of Science ®Google Scholar
• Fagan EA. Intrahepatic cholestasis of pregnancy. Clin. Liver Dis.3, 603–632 (1999).
   PubMedGoogle Scholar
• Glantz A, Marschall HU, Lammert F, Mattson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology42, 1399–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Aractingi S, Berkane N, Bertheau P et al. Fetal DNA in skin of polymorphic eruption of pregnancy. Lancet352, 1898–1901 (1998).
   PubMed Web of Science ®Google Scholar
• Appleton Al, Curtis A, Wilkens J, Cant AJ. Differentiation of materno–fetal GVHD from Ommen’s syndrome in pre-BMT patients with severe combined immunodeficiency. Bone Marrow Transplant.14, 157–159 (1994).
   PubMed Web of Science ®Google Scholar
• Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin. Obstet. Gynecol.8, 443–468 (1994).
   PubMed Web of Science ®Google Scholar
• Strevens H, Wide-Swensson D, Hansen A et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG110, 831–836 (2003).
   PubMed Web of Science ®Google Scholar
• Subramanya A, Houghton D, Watnick S. Steroid-responsive idiopathic glomerular capillary endotheliosis: case report and literature review. Am. J. Kidney Dis.45, 1090–1095 (2005).
   PubMed Web of Science ®Google Scholar
• Arias F, Mancilla-Jimenez R. Hepatic fibrinogen deposits in pre-eclampsia. Immunofluorescent evidence. N. Engl. J. Med.295, 578–582 (1976).
   PubMed Web of Science ®Google Scholar
• Rolfes DB, Ishak KG. Liver disease in toxemia of pregnancy. Am. J. Gastroenterol.81, 1138–1144 (1986).
   PubMed Web of Science ®Google Scholar
• Ray RA, Lewin KJ, Colonna J, Goldstein LI, Busuttil RW. The role of liver biopsy in evaluating acute allograft dysfunction following liver transplantation: a clinical histologic correlation of 34 liver transplants. Hum. Pathol.19, 835–848 (1988).
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Papadimitriou JC, Farney A et al. Pancreas transplantation: the histology morphology of graft loss and correlation. Transplantation 27, 71, 1784–1791 (2001).
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant.11, 945–956 (2005).
   PubMed Web of Science ®Google Scholar
• Shulman HM, Kleiner D, Lee SJ et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol. Blood Marrow Transplant.12, 31–47 (2006).
   PubMed Web of Science ®Google Scholar
• Hiesse C, Goldschmidt E, Santelli G, Charpentier B, Machover D, Fries D. Membranous nephropathy in a bone marrow recipient. Am. J. Kidney Dis.11, 188–191 (1998).
   Google Scholar
• Otani M, Shimojo H, Shiozawa S, Shigematsu H. Renal involvement in bone marrow transplantation. Nephrology (Carlton)10, 530–536 (2005).
   PubMed Web of Science ®Google Scholar
• Gorcynski RM, Hadidi S, Yu G, Clark DA. The same immunoregulatory molecules contribute to successful pregnancy and transplantation. Am. J. Reprod. Immunol.48, 18–26 (2002).
   PubMed Web of Science ®Google Scholar
• Wilzynski JR. Immunological analogy between allograft rejection, recurrent abortion and preeclampsia – the same basic mechanism? Hum. Immunol.67, 492–511 (2006).
   PubMed Web of Science ®Google Scholar
• Rappaport VJ, Hirata G, Yap HK, Jordan AC. Anti-vascular endothelial cell antibodies in severe preeclampsia. Am. J. Obstet. Gynecol.162, 138–145 (1990).
   PubMed Web of Science ®Google Scholar
• El-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol.164, 1253–1261 (1991).
   PubMed Web of Science ®Google Scholar
• Milliez J, Lelong F, Bayani N et al. The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation. Am. J. Obstet. Gynecol.165, 51–56 (1991).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yoshimura S, Geshi Y et al. Measurement of antiphospholipid antibody by ELISA using purified β2-glycoprotein in preeclampsia. Immunology94, 196–200 (1993).
   Web of Science ®Google Scholar
• Branch DW, Mitchell MD, Miller E, Palinski W, Witzum JL. Preeclampsia and serum antibodies to oxidized low-density lipoprotein. Lancet343, 645–646 (1994).
   PubMed Web of Science ®Google Scholar
• Anderson BE, McNiff J, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting ells and costimulatory molucles in murine chronic graft-versus-host disease: requirements depend on target organ. Blood105, 2227–2234 (2005).
   PubMed Web of Science ®Google Scholar
• Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood105, 4885–4891 (2005).
   PubMed Web of Science ®Google Scholar
• Raulet DH. Does low level expression of HLA molecules engender autoimmunity? N. Engl. J. Med.340, 278–284 (1999).
   PubMed Web of Science ®Google Scholar
• Goker H, Haznedaroglu IC, Chao NJ. Acute graft-versus-host disease pathobiology and management. Exp. Hematol.29, 259–277 (2001).
   PubMed Web of Science ®Google Scholar
• Miranda S, Litwin S, Barrientos G et al. Dendritic cells therapy confers a protective microenvironment in murine pregnancy. Scand. J. Immunol.64, 493–499 (2006).
   PubMed Web of Science ®Google Scholar
• Trivedi HL, Mishra VV, Vanikar AV et al. Embryonic stem cell derived and adult hematopoietic stem cell transplantation for tolerance induction in renal allograft recipient: a case report. Transplant. Proc.38, 3103–3108 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffman P, Edinger M. CD4+CD25+ regulatory T cells and graft versus host disease. Semin. Hematol.43, 62–69 (2006).
   PubMed Web of Science ®Google Scholar
• Zaya F, Bacigalupo A, Patriarca F et al. GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant.40, 273–277 (2007).
   PubMed Web of Science ®Google Scholar
• Knop S, Herbart H, Gratwohl A et al. Treatment of steroid-resistant acute GVHD with OKT3 and high dose steroids results in better disease control and lower incidence of infectious complications when compared to high dose steroids alone: a randomized muticenter trial by the EBMT Chronic Leukemia Working Party. Leukemia21, 1830–1833 (2007).
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticosteroids for mother and child. Am. J. Obstet. Gynecol.195, 914–934 (2006).
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Lima F, Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br. J. Rheumatol.35, 133–138 (1996).
   PubMedGoogle Scholar
• Samuel D, Riordan S, Strasser S, Kurtovic J, Singh-Grewel I, Koorey D. Severe autoimmune hepatitis first presenting in the early post partum period. Clin. Gastroenterol. Hepatol.2, 622–624 (2004).
   PubMed Web of Science ®Google Scholar
• Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet368, 687–693 (2006).
   PubMed Web of Science ®Google Scholar
• Nathanielsz PW. A time to be born. Implications of animal studies in maternal fetal medicine. Birth21, 163–169 (1994).
   PubMed Web of Science ®Google Scholar
• Russel CA. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Dan. Med. Bull.49, 89–108 (2002).
   PubMedGoogle Scholar
• Bertinetto FE, Dall’Omo AM, Mazzola GA et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int. J. Immunogenet.33, 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Annells MF, Hart PH, Mullighan CG et al. Interleukins-1,4,6,10, tumor necrosis factor, transforming growth factor-β, FAS, and mannose-binding protein C gene polymorphism in Australian women: Risk of preterm birth Am. J. Obstet. Gynecol.191, 2056–2067 (2004).
   PubMed Web of Science ®Google Scholar
• Speer EM, Gentile DA, Zeevi A, Pillage G, Huo D, Skoner DP. Role of single nucleotide polymorphism of cytokine genes in spontaneous preterm delivery. Hum. Immunol.67, 915–923 (2006).
   PubMed Web of Science ®Google Scholar
• Steinborn A, Gunes H, Roddiger S, Halberstadt E. Elevated placental cytokinerelease, a process associated with preterm labor in the absence of intrauterine infection. Obstet. Gynecol.88, 534–539 (1996).
   PubMed Web of Science ®Google Scholar
• Maymon E, Gheezi F, Edwin SS et al. The tumor necrosis factor alpha and its soluble receptor profile in term and preterm parturition. Am. J. Obstet. Gynecol.181, 1142–1148 (1999).
   PubMed Web of Science ®Google Scholar
• Alvarez-de-la-Rosa M, Rebollo FJ, Codoceo R, Gonzalez A. Maternal serum interleukin 1, 2–6, 8 and interleukin-2 receptor levels in preterm labor and delivery. Eur. J. Obstet. Gynecol. Reprod. Biol.88, 57–60 (2000).
   PubMed Web of Science ®Google Scholar
• Farina A, LeShane ES, Romero R et al. High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am. J. Obstet. Gynecol.193, 421–425 (2005).
   PubMed Web of Science ®Google Scholar
• Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin. Perinatol.30, 16–19 (2006).
   PubMed Web of Science ®Google Scholar
• Basso O, Rasmussen S, Weinberg CR, Wilcox AJ, Irgens LM, Skajaerven R. Trends in fetal and infant survival following preclampsia. JAMA296, 1357–1362 (2006).
   PubMed Web of Science ®Google Scholar
• Magann EF, Martin JN Jr, Isaacs JD, Perry KG Jr, Martin RW, Meydrech EF. Immediate postpartum curettage: accelerated recovery from severe preeclampsia. Obstet. Gynecol.81, 502–506 (1993).
   PubMed Web of Science ®Google Scholar
• Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst. Rev.25, CD004947 (2006).
   Google Scholar
• Ragusa A, de Carolis C, dal Lago A et al. Progesterone supplement in pregnancy: an immunologic therapy? Lupus13, 639–642 (2004).
   PubMed Web of Science ®Google Scholar
• Mowbray JF, Gibbings C, Liddell H, Reginald PW, Underwood JL, Beard RW. Controlled trial of treatment or recurrent spontaneous abortion by immunization with paternal cells. Lancet1, 941–943 (1985).
   PubMed Web of Science ®Google Scholar
• Coulam CB, Stephenson M, Stern JJ, Clark DA. Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am. J. Reprod. Immunol.35, 352–359 (1996).
   PubMed Web of Science ®Google Scholar
• Blanche P, Dreyfus F, Sicard D. Polymyositis and chronic graft-versus-host disease: efficacy of intravenous gammaglobulin and methotrexate. Clin. Exp. Rheumatol.13, 377–379 (1995).
   PubMed Web of Science ®Google Scholar
• Katz VL, Thorp JM Jr, Watson WJ, Fowler L, Heine RP. Human immunoglobulin therapy for preeclampsia associated with lupus anticoagulant and anticardiolipin antibody. Obstet. Gynecol.76, 986–988 (1990).
   PubMed Web of Science ®Google Scholar